title: Immune consequences of intraocular administration of modified adenoviral vectors.
abstract: To investigate the immune consequences of intraocular administration of modified adenoviral vectors, C57BL/6 normal and retinal degeneration C57BL/6 (rd/rd) mice were immunized with subcutaneous, subretinal, vitreal, or anterior chamber injections of replication-deficient adenovirus (AdV) containing the Escherichia coli beta-galactosidase gene (AdV-LacZ). Fourteen days after the initial inoculation, the animals were immune challenged with an injection of AdV-LacZ in the right ear pinna. Antigen-induced delayed type hypersensitivity (DTH) was measured by determining relative ear swelling. Normal C57BL/6 mice immunized with subretinal, vitreal, or anterior chamber injections did not demonstrate a DTH response. The rd/rd C57BL/6 mice injected in the anterior chamber with the viral construct also did not respond with DTH in a manner similar to normal mice responding to intraocular injection and subsequent challenge. However, the rd/rd C57BL/6 mice immunized by the subretinal or vitreal route did respond to immune challenge with a DTH response. Histologic examination of the eyes showed a lack of infiltration by inflammatory cells. Although these results suggest that the potential for immune consequences is reduced when modified adenoviral vectors are used in the normal ocular environment, these vectors used in the vitreal cavity of rd/rd animals may induce a systemic response to the vectors.
authors.affiliation: Department of Pediatrics, Texas Children's Cancer Center and Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.
authors.forename: M L
authors.initials: ML
authors.lastname: Suber
authors.forename: M Y
authors.initials: MY
authors.lastname: Hurwitz
authors.forename: P
authors.initials: P
authors.lastname: Chévez-Barrios
authors.forename: R L
authors.initials: RL
authors.lastname: Hurwitz
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D004279:DNA, Viral / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology*; D004423:Ear / Q000473:pathology; D005123:Eye / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology*; D006968:Hypersensitivity, Delayed / Q000276:immunology / Q000473:pathology; D007249:Inflammation / Q000276:immunology / Q000473:pathology; D007267:Injections / Q000009:adverse effects; D007279:Injections, Subcutaneous / Q000009:adverse effects; D007763:Lac Operon / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D012162:Retinal Degeneration / Q000235:genetics* / Q000276:immunology / Q000473:pathology / Q000628:therapy
chemical_list: D004279:DNA, Viral